聯合醫務(00722.HK)向主要股東出售內地醫療保健業務權益
聯合醫務(00722.HK)公布,全資附屬UMP Medical China向買方Big Ideas Ventures出售目標公司聯合醫務中國之55%已發行股本,現金代價2,200萬元。
聯合醫務中國為公司間接擁有80%權益之非全資附屬,其主要從事中國醫療保健行業之新興業務,聚焦大灣區市場。出售完成後,聯合醫務中國將由買方、公司及Laser Focus分別擁有55%、25%及20%之權益,其將不再為公司之附屬。
集團估計將在損益中實現出售事項的淨收益1,390萬元,擬將出售所得款項淨額用作一般營運資金。
買方Big Ideas Ventures為公司主要股東周大福企業之間接全資附屬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.